Initiation of KOMET-008 Phase 1 Clinical Trial by Kura Oncology with Ziftomenib and Standard Care Combinations for Acute Myeloid Leukemia Patients with Specific Genetic Alterations

Initiation of KOMET-008 Phase 1 Clinical Trial by Kura Oncology with Ziftomenib and Standard Care Combinations for Acute Myeloid Leukemia Patients with Specific Genetic Alterations Overview Company: Kura Oncology, Inc. Indication: Acute Myeloid Leukemia (AML) Drug: Ziftomenib Trial Phase: Phase 1 NCT ID: NCT06001788 Introduction On February 26, 2024, Kura Oncology, Inc., a company at the forefro..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 28.
  • textsms

Advancement in Acute Myeloid Leukemia Treatment: Kura Oncology Initiates Phase 1 KOMET-008 Trial with Ziftomenib in Combination Therapies

Advancement in Acute Myeloid Leukemia Treatment: Kura Oncology Initiates Phase 1 KOMET-008 Trial with Ziftomenib in Combination Therapies Overview Kura Oncology, Inc., a company leading the way in precision medicine for cancer, has begun a promising new clinical trial for Acute Myeloid Leukemia (AML) treatment. Clinical Trial Details Company: Kura Oncology, Inc. Indication: Acute Myeloid Leukemi..

  • format_list_bulleted Pharmacology/BS
  • · 2024. 2. 27.
  • textsms

Kura Hopes to Raise $100M in Public Offering on Heels of Clinical Data

Kura Oncology has announced plans for a $100 million underwritten public offering to fund the development of its three candidate drugs, invest pipeline research and development, and provide general working capital. The company has approximately $406 million in cash, cash equivalents and investments, which it expects will fund current operations until Q4 2025. However, Kura's pre-market share val..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms